{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:29Z","timestamp":1786118849335,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.jcrs.2007.07.012","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T10:00:49Z","timestamp":1196157649000},"page":"1991-1993","source":"Crossref","is-referenced-by-count":66,"title":["Subconjunctival bevacizumab for vascularized rejected corneal grafts"],"prefix":"10.1097","volume":"33","author":[{"given":"Ahmed","family":"Awadein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-45-20210210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization.","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"R2-45-20210210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":"Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"key":"R3-45-20210210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R4-45-20210210","first-page":"13","article-title":"Vascular endothelial growth factor and ocular neovascularization.","volume":"151","author":"Miller","year":"1997","journal-title":"Am J Pathol"},{"key":"R5-45-20210210","first-page":"1869","article-title":"Experimental inhibition of corneal neovascularization by endostatin gene transfection in vivo.","volume":"116","author":"Zhang","year":"2003","journal-title":"Chin Med J"},{"key":"R6-45-20210210","first-page":"961","article-title":"Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea.","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"R7-45-20210210","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-45-20210210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exer.1998.0527","article-title":"Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization.","volume":"67","author":"Gohto","year":"1998","journal-title":"Exp Eye Res"},{"key":"R9-45-20210210","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-45-20210210","first-page":"2510","article-title":"Inhibition of inflammatory corneal angiogenesis by TNP-470.","volume":"42","author":"Joussen","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-45-20210210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00417-002-0591-7","article-title":"Inhibition of experimental angiogenesis of cornea by somatostatin.","volume":"241","author":"Wu","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-45-20210210","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.06-0433","article-title":"Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.","volume":"47","author":"Costa","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335007013673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335007013673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.jcrs.2007.07.012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:02Z","timestamp":1786035302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02158034-200711000-00045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2007.07.012","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}